162 related articles for article (PubMed ID: 32850336)
1. LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation.
Zhao Z; Liang S; Sun F
Front Oncol; 2020; 10():1172. PubMed ID: 32850336
[TBL] [Abstract][Full Text] [Related]
2. LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer.
An Y; Chen XM; Yang Y; Mo F; Jiang Y; Sun DL; Cai HH
Cancer Cell Int; 2018; 18():143. PubMed ID: 30250401
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells.
Fu X; Tian Y; Kuang W; Wen S; Guo W
Exp Ther Med; 2019 Jun; 17(6):4715-4722. PubMed ID: 31105791
[TBL] [Abstract][Full Text] [Related]
4. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
[TBL] [Abstract][Full Text] [Related]
5. The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/β-catenin signaling pathway.
Guo J; Chen Z; Jiang H; Yu Z; Peng J; Xie J; Li Z; Wu W; Cheng Z; Xiao K
Cancer Cell Int; 2019; 19():312. PubMed ID: 31787849
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer.
You Q; Shi HY; Gong CF; Tian XY; Li S
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6429-6435. PubMed ID: 31378881
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells.
Wu DM; Zheng ZH; Zhang YB; Fan SH; Zhang ZF; Wang YJ; Zheng YL; Lu J
J Exp Clin Cancer Res; 2019 Jun; 38(1):237. PubMed ID: 31171015
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Huang Y; Ni R; Wang J; Liu Y
Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA DLX6-AS1 promotes neuroblastoma progression by regulating miR-107/BDNF pathway.
Zhang HY; Xing MQ; Guo J; Zhao JC; Chen X; Jiang Z; Zhang H; Dong Q
Cancer Cell Int; 2019; 19():313. PubMed ID: 31787850
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA DLX6-AS1 facilitates bladder cancer progression through modulating miR-195-5p/VEGFA signaling pathway.
Wang H; Niu X; Jiang H; Mao F; Zhong B; Jiang X; Fu G
Aging (Albany NY); 2020 Aug; 12(16):16021-16034. PubMed ID: 32756011
[TBL] [Abstract][Full Text] [Related]
12. DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer.
Liang Y; Zhang CD; Zhang C; Dai DQ
Gastric Cancer; 2020 Mar; 23(2):212-227. PubMed ID: 31463827
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer.
Yang J; Ye Z; Mei D; Gu H; Zhang J
Cancer Manag Res; 2019; 11():4209-4221. PubMed ID: 31118816
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA
Xie F; Xie G; Sun Q
Cancer Biother Radiopharm; 2020 Mar; 35(2):129-136. PubMed ID: 32077747
[No Abstract] [Full Text] [Related]
15. Long noncoding RNA DLX6-AS1 functions as a competing endogenous RNA for miR-577 to promote malignant development of colorectal cancer.
Zhou FR; Pan ZP; Shen F; Huang LQ; Cui JH; Cai K; Guo XL
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3742-3748. PubMed ID: 31115000
[TBL] [Abstract][Full Text] [Related]
16. LncRNA DLX6-AS1 increases the expression of HIF-1α and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR-199a-5p.
Yang B; Jia L; Ren H; Jin C; Ren Q; Zhang H; Hu D; Zhang H; Hu L; Xie T
Mol Genet Genomic Med; 2020 Jan; 8(1):e1017. PubMed ID: 31782911
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of long noncoding RNA DLX6-AS1 inhibits migration and invasion of thyroid cancer cells by upregulating UPF1.
Zhong ZB; Wu YJ; Luo JN; Hu XN; Yuan ZN; Li G; Wang YW; Yao GD; Ge XF
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10867-10873. PubMed ID: 31858555
[TBL] [Abstract][Full Text] [Related]
18. Promising long noncoding RNA DLX6-AS1 in malignant tumors.
Xue C; Lv L; Jiang J; Li L
Am J Transl Res; 2020; 12(12):7682-7692. PubMed ID: 33437353
[TBL] [Abstract][Full Text] [Related]
19. LncRNA
Sun W; Zhang L; Yan R; Yang Y; Meng X
Onco Targets Ther; 2019; 12():3945-3954. PubMed ID: 31190891
[No Abstract] [Full Text] [Related]
20. LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway.
Zhang N; Meng X; Mei L; Zhao C; Chen W
J Cell Biochem; 2019 Jul; 120(7):11478-11489. PubMed ID: 30838699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
